ARTICLE | Politics & Policy

FDA panel to review compounding revisions

January 24, 2015 2:16 AM UTC

FDA's Pharmacy Compounding Advisory Committee (PCAC) will meet on Feb. 23-24 to discuss proposed revisions to the agency's lists of bulk substances that may or may not be compounded under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

PCAC will discuss comments received on FDA's notice of proposed rulemaking that seeks to add 25 drug products to the list that cannot be compounded based on new data indicating they are unsafe or ineffective. ...